Provided by Tiger Trade Technology Pte. Ltd.

Acrivon Therapeutics, Inc.

2.13
+0.07003.40%
Post-market: 2.140.0100+0.47%16:29 EDT
Volume:184.29K
Turnover:386.97K
Market Cap:91.17M
PE:-1.13
High:2.14
Open:2.06
Low:2.06
Close:2.06
52wk High:3.56
52wk Low:1.27
Shares:42.80M
Float Shares:25.69M
Volume Ratio:0.94
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8800
EPS(LYR):-2.0151
ROE:-64.63%
ROA:-38.02%
PB:1.05
PE(LYR):-1.06

Loading ...

Acrivon Therapeutics Q1 net loss narrows

Reuters
·
May 14

Acrivon net loss narrows to $19 million in Q1 FY26

Reuters
·
May 14

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

THOMSON REUTERS
·
May 14

Acrivon Therapeutics, Inc Q1 Income From Operations USD -19.902 Million

THOMSON REUTERS
·
May 14

Acrivon Therapeutics announces annual shareholder meeting

Reuters
·
Apr 30

Acrivon flags preclinical synergy data for ACR-368, ACR-2316 with PD-L1 blockade

Reuters
·
Apr 18

BRIEF-Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Apr 16

Acrivon Therapeutics grants new hire options to buy 111,150 shares under inducement plan

Reuters
·
Apr 16

We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Simply Wall St.
·
Mar 27

Jefferies Keeps Their Buy Rating on Acrivon Therapeutics, Inc. (ACRV)

TIPRANKS
·
Mar 23

Acrivon Therapeutics Q4 net loss narrows as expenses fall

Reuters
·
Mar 19

BRIEF-Acrivon Therapeutics, Inc Q4 Income From Operations USD -20.116 Million

Reuters
·
Mar 19

Acrivon Therapeutics, Inc Q4 Net Income USD -18.985 Million

THOMSON REUTERS
·
Mar 19

Press Release: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Dow Jones
·
Mar 19

Acrivon FY 2025 net loss narrows 5.4% to USD 77.9 million as interest income falls 29.6% to USD 6.48 million

Reuters
·
Mar 19

Acrivon Therapeutics to present three posters at the AACR Annual Meeting

Reuters
·
Mar 18